The supposition that KRAS mutant tumor cells have constitutive and enhanced macropinocytosis drives an interesting question: could such enhanced macropinocytosis be distinctive enough to act as a “phenotypic target” for KRAS mutant cancer, where targeted therapeutics are urgently needed? The gene discussed is KRAS; the disease is cancer.